Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-02-06
2007-02-06
Spector, Lorraine (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S520000, C424S185100, C435S007100, C530S300000, C530S350000
Reexamination Certificate
active
10475711
ABSTRACT:
The present invention relates to a TGF-β1 binding protein called r150. This protein has a GPI-anchor contained in r150 itself and not on a tightly associated protein and that it binds TGF-β1 with an affinity comparable to those of the signaling receptors. Furthermore, the released (soluble) form of this protein binds TGF-β1 independent of the types I and II receptors. Also, the soluble form inhibits the binding of TGF-β to its receptor. In addition, evidence that r150 is released from the cell surface by an endogenous phospholipase C is provided. Also, the creation of a mutant human keratinocyte cell line with a defect in GPI synthesis which displays reduced expression of r150 is described. Our results using these mutant keratinocytes suggest that the membrane anchored form of r150 is a negative modulator of TGF-beta responses. These findings, taken together with the observation that r150 forms a heteromeric complex with the signaling receptors, suggest that this accessory receptor in either its membrane anchored or soluble form may antagonize TGF-β responses in human keratinocytes. Experiments with mutants confirmed that TGFβ1 activity can be modulated when the expression of the accessory receptor r150 is silenced. The complete nucleic acid and deduced amino acid sequences are now provided. The r150 cloned nucleic acid was used to study overexpression of r150. When r150 gene is overexpressed, TGFβ responses are increased. r150 and its derivatives or precursors (fragments, variants and nucleic acids encoding the same) will find a broad clinical utility, knowing that TGFβ1 is an important cytokine.
REFERENCES:
patent: WO 00/29448 (2000-05-01), None
patent: WO 02/070696 (2002-09-01), None
Lastres et al. 1996. J Cell Biol. 133:1109-1121.
Li et al. 1999. FASEB J. 14:55-64.
Onichtchouk et al. 1999. Nature. 401:480-485.
Abrami, L. et al., The Journal of Biological Chemistry, 2001, vol. 276, No. 33, pp. 30729-30736.
Akhurst, R.J. et al., TRENDS in Cell Biology, 2001, vol. 11, No. 11, pp. S44-S51.
Blacker, D. et al., Nature America Inc., 1998. vol. 19, pp. 357-360.
Blobe, G.C. et al., The New England Journal of Medicine, 2000. vol. 342, pp. 1350-1358.
Border, W.A. et al., Letters to Nature—Nature Publishing Group, 1990. vol. 346, pp. 371-374.
Bordier, C., The Journal of Biological Chemistry, 1981, vol. 256, No. 4, pp. 1604-1607.
Boukamp, P. et al., The Journal of Cell Biology, 1988, vol. 106, pp. 761-771.
Boyd, F.T. et al., The Journal of Biological Chemistry, 1989, vol. 264, No. 4, pp. 2272-2278.
Broomfield, S.J. et al., Biochimica et Biophysica Acta, 1993, 1145, pp. 212-218.
Brown, D., Current Opinion in Immunolgy-Current Biology Ltd, 1993, vol. 5, pp. 349-354.
Brown, D.A. et al., Annu. Rev. Cell Dev. Biol., 1998, 14, pp. 111-136.
Chajek-Shaul, T. et al., Biochimica et Biophysica Acta, 1989, 1014, pp. 178-183.
Charng, M-J. et al., The Journal of Biological Chemistry, 1998, vol. 273, No. 16, pp. 9365-9368.
Cheifetz, S. et al., The Journal of Biological Chemistry, 1991, vol. 226, No. 31, pp. 20767-20772.
Cheifetz, S. et al., The Journal of Biological Chemistry, 1992, vol. 267, No. 27, pp. 19027-19030.
Chen, R. et al., Proc. Natl. Acad. Sci. USA, 1998, vol. 95, pp. 9512-9517.
Chen, R-H. et al., Letters to Nature—Nature, 1995, vol. 377, pp. 548-552.
Chen, Y-G. et al., The EMBO Journal, 1997, vol. 16, No. 13, pp. 3866-3876.
Choi, B-M. et al., Immunology and Cell Biology, 1996, 74, pp. 144-150.
Choi, M-E., American Physiological Society, 1999, 276, pp. F88-F95.
Choy, L. et al., The Journal of Biological Chemistry, 1998, vol. 273, No. 47, pp. 31455-31462.
Clark, R.A.F., The Molecular and Cellular Biology of Wound Repair, Second Edition, Plenum Press, 1996, pp. 3-35.
Datta, P.K. et al., The Journal of Biological Chemistry, 1998, vol. 273. No. 52. pp. 34671-34674.
Datta, P. K. et al., Molecular and Cellular Biology, 2000, vol. 20, No. 9, pp. 3157-3167.
Draper, L.B. et al., The Journal of Biological Chemistry, 1998, vol. 271, No. 1, pp. 398-403.
Dumont, N. et al., Molecular and Cellular Endocrinology, 1995, 111, pp. 57-66.
Germain, L. et al., Burns, 1993, 19, (2), pp. 99-104.
Glick, A.B. et al., Proc. Natl. Acad. Sci. USA, 1993, vol. 90, pp. 6076-6080.
Glick, A.B. et al., Genes & Development, 1994, vol. 8, pp. 2429-2440, only abstract provided.
Gonias, S.L. et al., The Journal of Biological Chemistry, 2000, vol. 275, No. 8, pp. 5826-5831.
Gougos, A. et al., The Journal of Biological Chemistry, 1990, vol. 265, No. 15, pp. 8361-8364.
Grainger, D.J, et al., Biol. Rev., 1995, 70, pp. 571-596.
Gressner, A.M. et al., Frontiers in Bioscience 7, 2002, d793-807.
Griswold-Penner, I. et al., Molecular and Cellular Biology, 1998. pp. 6595-6604.
Hebda, P.A., The Journal of Investigative Dermatology, vol. 91, No. 5, pp. 440-445.
Heldin, C.H. et al., Nature, 1997, vol. 390, pp. 465-471.
Hojo, M. et al., Nature, 1999, vol. 397, pp. 530-534.
Hooper, N.M., Identification of glycosyl-phosphatidylinositol . . . In Hooper NM and Turner AJ, 1995, A Practical Approach. 1NY: IRL Press. pp. 89-115.
Hooper, N.M., Mol Membr Biol, 1999, 16 (2), pp. 145-156, abstract only.
Horejse, V. et al., Viewpoint Immunology Today, 1999, vol. 20, No. 8, pp. 356-361.
Huse, M. et al., Cell, 1999, vol. 96, pp. 425-436.
Isaka, Y. et al., Nature Medicine, 1996, vol. 2, pp. 418-423.
Isaka, Y. et al., Kidney International, 1999, vol. 55, pp. 465-475.
Kawabata, M. et al., The Journal of Biological Chemistry, 1995, vol. 270, No. 50, pp. 29628-29631.
Khalil, N. et al., Ciba Found Symp. 1991, 157, pp. 194-207, abstract only.
Kingsley, D.M., Genes & Development, 1994, 8, pp. 133-146.
Kirsch, T. et al., Physiologische Chemie II—FEBS Letters 468, 2000, pp. 215-219.
Laiho, M. et al., The Journal of Biological Chemistry, 1990, vol. 265, No. 30, pp. 18518-18524.
Lefer, A.M. et al., Proc. Natl. Acad. Sci USA, Physiology, 1993, vol. 90, pp. 1018-1022.
Lefer, A.M. et al., Science, 1990, vol. 249, 4964, Research Library Core, pp. 61-64.
Letamendia, A. et al., The Journal of Biological Chemistry, 1998, vol. 273, No. 49, pp. 33011-33019.
Letterio, J.J. et al., Annu. Rev. Immunol., 1998, 16, pp. 137-161.
Li, C. et al., The FASEB Journal, 2000, vol. 14, pp. 55-64.
Lin, M. et al., BLOOD, 2002, vol. 99, No. 5, pp. 1683-1691.
Lisanti, M.P. et al., The Journal of Cell Biology, 1994, vol. 126, No. 1, pp. 111-126.
Lisanti, M.P. et al., Proc. Natl. Acad. Sci. USA, 1988, vol. 85, pp. 9557-9561.
Liu, J. et al., The Journal of Biological Chemistry, 1997, vol. 272, No. 11, pp. 7211-7222.
Lopez-Casillas, F. et al., The Journal of Cell Biology, 1994, vol. 124, No. 4, pp. 557-568.
Lopez-Casillas, F. et al., Cell, 1993, 73(7), pp. 1435-1444, Abstract only.
Luo, K. et al., The EMBO Journal, 1997, vol. 16, No. 8, pp. 1970-1981.
Markowitz, S. et al., Science, 1995, 268, 5215, pp. 1336-1338.
Massagué, J., Annu. Rev. Biochem. 1998, 67 pp. 753-791.
Massagué, J. et al., Cell, 2000, vol. 103, pp. 295-309.
McCaffrey, T.A., Cytokine & Growth Factor Reviews 11, 2000, 103-114.
McNeill, H. et al., Clinical Neuroscience and Neuropathology, 1994, NeuroReport 5, pp. 901-904.
Mehta, J.L. et al., Growth Factors, 1999, vol. 16, pp. 179-190.
Metz, C.N. et al., The EMBO Journal, 1994, vol. 13, No. 7, pp. 1741-1751.
Moulin, V. et al., 1997, Journal of Cellular Physiology, 171, pp. 1-10.
Movahedi, S. et al., Biochem. J., 1997, 326, pp. 531-537.
Mustoe, T.A. et al., Science, 1987, vol. 237, pp. 1333-1336.
Neer, E.J. et al., Nature, 1994, vol. 371, pp. 297-300.
Nosjean, O. et al., Biochimica et Biophysica Acta, 1997, 1331, pp. 153-186.
Nunes, I. et al., Cancer Research 56, 1997, pp. 495-499.
Oka, N. et al., The Journal of Biological Chemistry, 1997, vol. 272, No. 52, pp. 33416-33421.
Onichtchouk, D. et al., Nature, 1999, vol. 401, pp. 480-485.
Pasch, M.C. et al., The Society for Investigative Dermatology, Inc. , 1998, vol. 111, pp. 683-688.
Patel, B.N. et al., The Journal of Biological Chemistry, 1997, vol. 272, No. 32, pp. 20185-20190.
Peltonen, J. et al., J Invest Dermatol. 1991, 97(2), pp. 240-248, a
Philip Anie
Tam Betty
Goudreau Gage Dubuc
McGill University
Shafer Shulamith H.
Spector Lorraine
LandOfFree
150 KDA TGF-B1 accessory receptor acts a negative modulator... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 150 KDA TGF-B1 accessory receptor acts a negative modulator..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 150 KDA TGF-B1 accessory receptor acts a negative modulator... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3876295